Safety and tolerability of antipsychotics: focus on amisulpride

References

• LahtiACWeilerMAHolcombHHTammingaCACarpenterWTMcMahonRCorrelations between rCBF and symptoms in two independent cohorts of drug-free patients with schizophreniaNeuropsychopharmacology20063122123016123774
   PubMed Web of Science ®Google Scholar
• MeltzerHYWhat’s atypical about atypical antipsychotic drugs?Curr Opin Pharmacol20044535715018839
   PubMed Web of Science ®Google Scholar
• RobertsonGSMatsumuraHFibigerHCInduction patterns of fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activityJ Pharmacol Exp Ther1994271105810667965768
   PubMed Web of Science ®Google Scholar
• de OliveiraIRRibeiroMGFregonezeJBde SenaEPde CastroESilvaERegional c-fos expression in rat brain may predict antipsychotic therapeutic windowJ Clin Psychopharmacol20002070570611106148
   PubMed Web of Science ®Google Scholar
• GeddesJFreemantleNHarrisonPBebbingtonPAtypical antipsychotics in the treatment of schizophrenia: Systematic overview and meta-regression analysisBMJ20003211371137611099280
   PubMed Web of Science ®Google Scholar
• KapurSPsychosis as a state of aberrant salience: A framework linking biology, phenomenology, and pharmacology in schizophreniaAm J Psychiatry2003160132312505794
   PubMed Web of Science ®Google Scholar
• MeltzerHYThe role of serotonin in antipsychotic drug actionNeuropsychopharmacology199921106115
   PubMed Web of Science ®Google Scholar
• SchoemakerHClaustreYFageDNeurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivityJ Pharmacol Exp Ther199728083978996185
   PubMed Web of Science ®Google Scholar
• LeuchtSPitschel-WalzGEngelRRKisslingWAmisulpride, an unusual “atypical” antipsychotic: A meta-analysis of randomized controlled trialsAm J Psychiatry200215918019011823257
   PubMed Web of Science ®Google Scholar
• DavisJMChenNGlickIDA meta-analysis of the efficacy of second-generation antipsychoticsArch Gen Psychiatry2003655356412796218
   PubMed Web of Science ®Google Scholar
• de OliveiraIRMiranda-ScippaAMde SenaEPRisperidone versus haloperidol in the treatment of schizophrenia: a meta-analysis comparing their efficacy and safetyJ Clin Pharm Ther1996213493589119918
   PubMed Web of Science ®Google Scholar
• LeuchtSCorvesCArbterDEngelRRLiCDavisJMSecond-generation versus first-generation antipsychotic drugs for schizophrenia: A meta-analysisLancet2009373314119058842
   PubMed Web of Science ®Google Scholar
• WetzelHGrunderGHillertAAmisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology – a double-blind controlled study comparing a selective D2-like antagonist to a mixed D1-/D2-like antagonist. The Amisulpride Study GroupPsychopharmacology (Berl)19981372232329682999
   PubMed Web of Science ®Google Scholar
• SleightAJCaroloCPetitNZwingelsteinCBoursonAIdentification of 5-hydroxytryptamine7 receptor binding sites in rat hypothalamus: Sensitivity to chronic antidepressant treatmentMol Pharmacol199547991037838138
   PubMed Web of Science ®Google Scholar
• MullinsULGianutsosGEisonASEffects of antidepressants on 5-HT7 receptor regulation in the rat hypothalamusNeuropsychopharmacology19992135236710457532
   PubMed Web of Science ®Google Scholar
• AbbasAIHedlundPBHuangXPTranTBMeltzerHYRothBLAmisulpride is a potent 5-HT7 antagonist: Relevance for antidepressant actions in vivoPsychopharmacology (Berl)200920511912819337725
   PubMed Web of Science ®Google Scholar
• KvachninaELiuGDityatevA5-HT7 receptor is coupled to G alpha subunits of heterotrimeric G12-protein to regulate gene transcription and neuronal morphologyJ Neurosci2005257821783016120784
   PubMed Web of Science ®Google Scholar
• DalmauABergmanBBrismarBSomatic morbidity in schizophrenia a case control studyPublic Health19971113933979392971
   PubMed Web of Science ®Google Scholar
• HarrisECBarracloughBExcess mortality of mental disorderBr J Psychiatry199817311539850203
   PubMed Web of Science ®Google Scholar
• KurzthalerIFleischhackerWWThe clinical implications of weight gain in schizophreniaJ Clin Psychiatry200162Suppl 7323711346194
   PubMed Web of Science ®Google Scholar
• AllisonDBCaseyDEAntipsychotic-induced weight gain: A review of the literatureJ Clin Psychiatry200162Suppl 7223111346192
   PubMed Web of Science ®Google Scholar
• AllisonDBMackellJAMcDonnellDDThe impact of weight gain on quality of life among persons with schizophreniaPsychiatr Serv20035456556712663847
   PubMed Web of Science ®Google Scholar
• WernekeUTaylorDSandersTAOptions for pharmacological management of obesity in patients treated with atypical antipsychoticsInt Clin Psychopharmacol20021714516012131598
   PubMed Web of Science ®Google Scholar
• WeidenPJMackellJAMcDonnellDDObesity as a risk factor for antipsychotic noncomplianceSchizophr Res200466515714693352
   PubMed Web of Science ®Google Scholar
• de HertMAvanWRvanEDPrevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medicationSchizophr Res200683879316481149
   PubMed Web of Science ®Google Scholar
• McEvoyJPMeyerJMGoffDCPrevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES IIISchizophr Res200580193216137860
   PubMed Web of Science ®Google Scholar
• BaiYMChenJYYangWSAdiponectin as a potential biomarker for the metabolic syndrome in Chinese patients taking clozapine for schizophreniaJ Clin Psychiatry2007681834183918162013
   PubMed Web of Science ®Google Scholar
• BuisWPatient’s opinions concerning side effects of neurolepticsAm J Psychiatry19921498448451350429
   PubMed Web of Science ®Google Scholar
• CaseyDSide effect profiles of new antipsychotic agentsJ Clin Psychiatry19965740458941170
   PubMed Web of Science ®Google Scholar
• KerwinRWThe new atypical antipsychotics. A lack of extra pyramidal side-effects and new routes in schizophrenia researchBr J Psychiatry19941641411487513599
   PubMed Web of Science ®Google Scholar
• KaneJMClozapine in the treatment of schizophreniaEncephale1996227119102320
   PubMed Web of Science ®Google Scholar
• LiebermanJAStroupTSMcEvoyJPClinical antipsychotic trials of intervention effectiveness (CATIE) investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophreniaN Engl J Med20053531209120316172203
   PubMed Web of Science ®Google Scholar
• ColonnaLSaleemPDondey-NouvelLReinWLong term safety and efficacy of amisulpride in subchronic or chronic schizophreniaInt Clin Psychopharmacol200015132210836281
   PubMed Web of Science ®Google Scholar
• CarrièrePBonhommeDLemperièreTAmisulpride has a superior benefit/risk profile to haloperidol in schizophreniaEur Psychiatry20001532132911032464
   PubMed Web of Science ®Google Scholar
• PeuskensJBechPMöllerHJBaleRFleurotOReinWAmisulpride versus risperidone in the treatment of acute exacerbations of schizophreniaPsychiatry Res19998810711710622347
   PubMed Web of Science ®Google Scholar
• SechterDPeuskensJFleurotOAmisulpride vs risperidone in chronic schizophrenia: Results of a 6-month double-blind studyNeuropsychopharmacology2002271071108112464464
   PubMed Web of Science ®Google Scholar
• MartinSLjoHPeuskensJA double-blind, randomized comparative trial of amisulpride versus olanzapine in the treatment of schizophrenia: Short-term results at two monthsCurr Med Res Opin20021835536212442883
   PubMed Web of Science ®Google Scholar
• MortimerAMartinSLooHA double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophreniaInt Clin Psychopharmacol200419636915076013
   PubMed Web of Science ®Google Scholar
• LeuchtSWagenpfeilSHamannJAmisulpride is an atypical antipsychotic associated with low weight gainPsychopharmacology (Berl)200417311211514647963
   PubMed Web of Science ®Google Scholar
• TandonRSection of Pharmacopsychiatry; World Psychiatric Association. World Psychiatric Association Pharmacopsychiatry SectionSchizophr Res2008100203818243663
   PubMed Web of Science ®Google Scholar
• MotlováLAre there any differences in the efficacy among second generation antipsychotics in the treatment of schizophrenia and related disorders?Ann Clin Psychiatry20071913314317612853
   PubMedGoogle Scholar
• American Psychiatric Association2008 Practice guidelines for the treatment of patients with schizophrenia. Available from: http://www.psychiatryonline.com/pracGuide/pracGuideChapToc_6.aspx. Accessed Jul 29, 2010.
   Google Scholar
• NewcomerJWSecond-generation (atypical) antipsychotics and metabolic effects: A comprehensive literature reviewCNS Drugs200519Suppl 119315998156
   PubMed Web of Science ®Google Scholar
• LinCCBaiYMWangYCImproved body weight and metabolic outcomes in overweight or obese psychiatric patients switched to amisulpride from other atypical antipsychoticsJ Clin Psychopharmacol20092952953619910716
   PubMed Web of Science ®Google Scholar
• RettenbacherMAEbenbichlerCHoferAEarly changes of plasma lipids during treatment with atypical antipsychoticsInt Clin Psychopharmacol20062136937217012984
   PubMed Web of Science ®Google Scholar
• LecrubierYAmisulpride: Progress and outcomesCurr Med Res Opin200218Suppl 3182211999141
   PubMed Web of Science ®Google Scholar
• SaleemPOliéJPLooHSocial functioning and quality of life in the schizophrenic patient: Advantages of amisulprideInt Clin Psychopharmacol2002171811806403
   PubMed Web of Science ®Google Scholar
• WeidenPAquilaRStandardJAtypical antipsychotic drugs and long-term outcome in schizophreniaJ Clin Psychiatry199657Suppl 1153608941171
   PubMed Web of Science ®Google Scholar
• FranzMLisSPluddemannKGallhoferBConventional versus atypical neuroleptics: Subjective quality of life in schizophrenic patientsBr J Psychiatry19971704224259307690
   PubMed Web of Science ®Google Scholar
• CoulouvratCDondey-NouvelLSafety of amisulpride (Solian): A review of 11 clinical studiesInt Clin Psychopharmacol19991420921810468313
   PubMed Web of Science ®Google Scholar
• de OliveiraIRJuruenaMFTreatment of psychosis: 30 years of progressJ Clin Pharm Ther20063152353417176358
   PubMed Web of Science ®Google Scholar